top of page
.png){kind=logo}
Hybrid Exhibition
1 - 3 October 2021
Foyer, William Mong M.W. Building,
LKS Faculty of Medicine, ​
The University of Hong Kong
Roundtable Session Sponsor
LIXIANA ® - Superior reduction in major bleeding vs. well-managed warfarin
1
1. Giugliano RP, et al. N Engl Med. 2013; 369 (22): 2093-2104.
LIXIANA ® - The only NOAC with significant reduction in CV and all cause mortality in Asian
2*
2. Chiang CE, et al. J Arrhythm. 2017; 33: 345-367.
NOAC: Novel oral anticoagulants; CV: cardiovascular
* Compare with warfarin
LIXIANA ® - Can be co-administered with other commonly used cardiovascular agents
3,4
3. Steffel J, et al. EP Europace, 2021; euab065, Available at https://doi.org/10.1093/europace/euab065. Last accessed on 16 Aug, 2021
4. Hong Kong Lixiana Package Insert Jul 2019.
Contact us
bottom of page